Diatex, Inc.

Ferrokin Biosciences, Inc.

Celgene Corporation

Cymabay Therapeutics, Inc.

Metabolex, Inc.

Pfizer Corporation

Noramco Gmbh

Cornerstone Therapeutics, Inc.

Jason A Hanko

Eric J Hagen

Edward D Daugs

David H Louks

Stephan D Parent

Patricia Andres

Hugh Young Rienhoff, Jr

Amy E Tapper

Huamin Zhang

Valeriya N Smolenskaya

Jeffrey Stults

David Alan Engers

Petinka I Vlahova

Stuart Dimock

The present invention provides crystalline solid and amorphous forms of (&#x2212;)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (&#x2212;)-halofenate.

Crystalline solid and amorphous forms of (&#x2212;)-halofenate and methods related thereto

The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.

Romidepsin solid forms and uses thereof

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

The present invention is directed to novel crystalline and amorphous forms of nalbuphine hydrochloride.

Crystalline and amorphous forms of nalbuphine hydrochloride

Crystalline solid and amorphous forms of (&#x2212;)- halofenate and methods related thereto

Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.

Crystal form and pharmaceutical compositions of (+)-R-zileuton

The present invention relates to crystalline forms of (3S)-3-[N&#x2014;(N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2&#x2032;,3&#x2032;,5&#x2032;,6&#x2032;-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis. 

Crystalline forms

Growing community of inventors

West Lafayette, IN, United States of America

Jason A Hanko